It is estimated that 80 to 90% of drugs under development never make it to the marketplace due to insufficient clinical activity, unacceptable toxicity, rapid appearance of drug resistance, or other factors that should be, at least partially, predictable from preclinical testing. This new text asks the question, "How can we use computational method

Introduction: The Preclinical and Clinical Drug Development Process Physiological Pharmacokinetic Modeling Interspecies Scaling Prediction of Drug Metabolism and Toxicity Pharmacodynamic Modeling Cytokinetic Modeling Prediction of Drug Resistance Conclusions: The Virtual Clinical Trial References Appendix: Computational Pharmacology Software Suppliers Abbreviations Index